Osteotech, Inc. is a global leader in the processing of human bone and connective tissue for transplantation and an innovator in the development, manufacturing and marketing of biologic, biomaterial and device systems for musculoskeletal surgery. With a particular focus on spinal, trauma, and total joint revision procedures, the Company's current and development-stage technologies address needs within numerous musculoskeletal disciplines.Our strategy leverages our core competency in biological sciences, to fulfill unmet clinical needs of the worldwide orthopaedic surgical community. As a technology leader in orthobiologics, we focus on creating and redefining select orthopaedic market segments through the application of innovative regeneration technologies. Additionally, we have business alliances and product development initiative that are aimed at providing a broad base of unique non-biologic technologies that work in concert with our biologically active tissue forms. The combination of these technology platforms, coupled with our distribution network, offer the potential for consistent revenue and pre-tax profit growth. Since its formation in 1986, the Company has become the world's largest processor of aseptic allograft bone tissue yielding over 4.5 million grafts. Used in spinal fusions, to replace cancerous tissue, fill voids caused by trauma, augment prostheses and replace damaged ligaments and tendons, bone tissues processed by Osteotech improve the quality of life for more than 500 transplant recipients every day. In addition, the Company has acquired 90% of OST Developpement in France, which will enable the Company to expand its allograft business throughout Western Europe.
